Nachrichten

ESC 2024 - Programmauswahl

Überwältigt von der Anzahl der Talks, Diskussionen und Präsentationen des diesjährigen Kongresses der European Society of Cardiology in London? Hier eine Auswahl des Programms mit DZHK-Beteiligung in chronologischer Reihenfolge (GMT+1):

© Sabrina Mazzeo/Unsplash

Incidence and predictors of weaning failure from veno-arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock, Angela Dettling - Hamburg, 30. August 8:00-8:50

Acute coronary syndromes - get ready for the session, Raphael Twerenbold – Hamburg, 30. August, 8:15-9:15

What’s hot in pulmonary hypertension?, Norbert Frey – Heidelberg, 30. August, 8:15-9:45

Patients with cardiac arrest should be excluded from cardiogenic shock trials: con, Holger Thiele – Leipzig, 30. August, 8:15-9:45

Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter - discussion, Renate B Schnabel – Hamburg, 30. August, 8:15-9:45

Assessing the alignment of obstructive hypertrophic cardiomyopathy pharmacological treatments with ESC guidelines in Germany, Farbod Sedaghat-Hamedani - Heidelberg, 30. August, 13:00-13:50

Neurovascular crosstalk in atherosclerosis, Christian Weber – München, 30. August, 13:45-15:00

Artificial intelligence-based management of arrhythmias, Renate B Schnabel – Hamburg, 31. August, 8:15-9:45

Effectiveness of empagliflozin in patients with heart failure and COPD: Results from EMPEROR-Preserved and EMPEROR-Reduced, Stephan von Haehling – Göttingen, 31. August, 9:30-10:30

Genomic and metabolomics in cardiovascular medicine, Tanja Zeller – Hamburg, 31. August, 11:00-12:00

How digital is reshaping cardiac care, Gerhard Hindricks – Berlin, 31. August, 15:30-15:50

The role of mitochondrial dysfunction in atrial fibrillation, Niels Voigt – Göttingen, 31. August, 16:15-17:15

Discussant review – SWEDEGRAFT, Volkmar Falk – Berlin, 31. August, 16:15-17:21

Targeting the right patient for precision therapy, Stefanie Dimmeler – Frankfurt, 31. August, 17:30-18:30

Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis:  A subanalysis from the DEDICATE-DZHK6 trial, Sabine Bleiziffer - Bad Oeynhausen, 1. September, 8:15-9:45

When to use a pharmaco-invasive approach rather than primary PCI, Adnan Kastrati – München, 2. September, 8:15-9:45

Translational proteomics for cardiovascular disease (Prot4CVD Project), Claudia Langenberg – Berlin, 2. September, 11:00-12:00

Sex differences in heart-brain interactions: a neurology perspective, Matthias Endres – Berlin, 2. September, 11:00-12:00